Ghana

Discover our largest clinical study in Ghana which proved neoSCB’s effectiveness in real-world settings. The study confirmed the app’s accuracy in detecting newborn jaundice, highlighting its potential to enhance neonatal care in low-resource regions.


Listen to our BBC Tech Life (June 2022) coverage here:


Ghanaian clinicians trying the app.
The clinical study team meeting for discussion.

Our clinical study in Ghana, conducted between March 2019 and April 2020, involved 724 newborns and aimed to validate the neoSCB app’s efficacy in detecting neonatal jaundice. We validated neoSCB as an effective, non-invasive tool for neonatal jaundice detection, showing high sensitivity and specificity comparable to traditional methods.


  • Image Capture: A Samsung Galaxy S8 smartphone was used to take two images of each infant’s sclera—one with flash and one without. This allowed for ambient light subtraction, isolating the controlled illumination.
  • Calibration: A one-time calibration with an X-rite ColourChecker ensured accurate colour readings.
  • Comparison: The app’s scleral-conjunctival bilirubin readings were compared against traditional transcutaneous bilirubin meters (JM-105) and blood tests.
The equipment used in the clinical study.

Sensitivity and Specificity

neoSCB achieved a sensitivity of 0.94 and a specificity of 0.73, with a receiver operating characteristic (ROC) area under the curve (AUC) of 0.92.

Impact

Accessibility

Early Detection


The app’s smartphone technology’s success in detecting jaundice also hints at its potential for diagnosing other conditions, such as anemia which was also explored successfully in Ghana. This adaptability underscores this technology’s broader applicability in medical diagnostics.

Conclusions

The clinical study in Ghana confirmed that the neoSCB app, with its advanced image analysis and calibration techniques, will be a promising alternative to conventional jaundice screening methods. Its success underscores its potential to enhance neonatal care, especially in lower-income regions.

The study shows that the neoSCB app is as good as commercial devices currently recommended to screen for severely jaundiced newborns, but the app only requires a smartphone which costs less than a tenth of the commercial device. We hope that, once rolled out widely, our technology can be used to save the lives of newborns in parts of the world that lack access to expensive screening devices.

Dr Terence Leung / Principle Investigator (UCL)

The neoSCB method was acceptable to mothers in urban and rural communities where the study was conducted. Mothers easily devised ways to keep the baby’s eye open, most often by initiating breastfeeding.

Dr Christabel Enweronu-Laryea / Principle Investigator (University of Ghana medical School)